Liu Junfeng, Wang Deren, Li Jie, Lin Jing, Xiong Yao, Liu Bian, Wei Chenchen, Wu Bo, Ma Zhenxing, Zhang Shihong, Liu Ming
Department of Neurology, Stroke Clinical Research Unit, West China Hospital, Sichuan University, Chengdu, China.
Department of Neurology, People's Hospital of Deyang City, Deyang, China.
Curr Neurovasc Res. 2017;14(2):104-109. doi: 10.2174/1567202614666170313111251.
Cerebral microbleeds (CMBs) are known to be potential risk factors for intracerebral hemorrhage (ICH), but there is controversy on the relationship between CMBs and hemorrhagic transformation (HT) after ischemic stroke. Besides, the question regarding whether the relationship between CMBs and HT can be affected by antithrombotic drugs in acute stage of ischemic stroke has not yet reached a consensus.
174 acute ischemic stroke patients with atrial fibrillation (AF) and/or rheumatic heart disease (RHD) were prospectively and consecutively enrolled in the study, of which 160 patients (mean 68.09 ±12.59 years) were finally included in the final analysis (West China Hospital, Sichuan University, n=125; People's Hospital of Deyang City, n=35).We assessed the presence, location and number of CMBs by using susceptibility-weighted imaging (SWI) within 7 days after admission, and the incidence of hemorrhagic transformation was evaluated by magnetic resonance imaging(MRI) during hospitalization. The univariate and multivariate analyses were used to analyze the relationship between CMBs and HT.
CMBs were detected in 90 patients (56.3%). HT was found in 62 (38.8%) patients, among which 43 were hemorrhagic infarction (HI) and 19 were parenchymal haemorrhage (PH). The presence of CMBs was not significantly different among different HT subtypes (no HT, HI and PH; 59.2%, 51.2%, versus 52.6%, P=0.64). There was no relationship between the number/location of CMBs and hemorrhagic transformation subtypes (P=0.38). In the 2 subgroups of patients treated with anticoagulants and antiplatelets after admission, the incidence of HT was not significantly different between patients with and without CMBs (anticoagulants, 13.3% versus 18.2%, P=0.71; antiplatelets, 29.2% versus 40.3%, P= 0.21).
The present study suggests that CMBs do not predict the presence of hemorrhagic transformation in acute ischemic stroke patients with AF and/or RHD. The results were not affected by anticoagulant or antiplatelet agents used in acute stage of ischemic stroke.
脑微出血(CMBs)被认为是脑出血(ICH)的潜在危险因素,但CMBs与缺血性卒中后出血性转化(HT)之间的关系存在争议。此外,关于CMBs与HT之间的关系是否会受到缺血性卒中急性期抗血栓药物的影响这一问题尚未达成共识。
前瞻性连续纳入174例患有心房颤动(AF)和/或风湿性心脏病(RHD)的急性缺血性卒中患者,最终160例患者(平均年龄68.09±12.59岁)纳入最终分析(四川大学华西医院125例;德阳市人民医院35例)。我们在入院后7天内使用磁敏感加权成像(SWI)评估CMBs的存在、位置和数量,并在住院期间通过磁共振成像(MRI)评估出血性转化的发生率。采用单因素和多因素分析来分析CMBs与HT之间的关系。
90例患者(56.3%)检测到CMBs。62例(38.8%)患者发生HT,其中43例为出血性梗死(HI),19例为实质内出血(PH)。不同HT亚型(无HT、HI和PH)中CMBs的存在情况无显著差异(分别为59.2%、51.2%和52.6%,P=0.64)。CMBs的数量/位置与出血性转化亚型之间无相关性(P=0.38)。在入院后接受抗凝和抗血小板治疗的2个亚组患者中,有CMBs和无CMBs患者的HT发生率无显著差异(抗凝治疗:13.3%对18.2%,P=0.71;抗血小板治疗:29.2%对40.3%,P=0.21)。
本研究表明,CMBs不能预测AF和/或RHD急性缺血性卒中患者出血性转化的存在。结果不受缺血性卒中急性期使用的抗凝或抗血小板药物的影响。